Canadian Urological Association (CUA)
123 episodes - English - Latest episode: 5 months ago -The official podcast of the Canadian Urological Association (CUA).
Le podcast officiel de l'association des urologues du Canada (AUC).
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Canadian Expert discussion on optimizing RCC treatment
November 29, 2023 19:14 - 42 minutes - 38.7 MBEpisode Notes Podcast Host Disclosures: Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, T...
2 Pees In A Pod Podcast - Ep 4 - Introduction to bladder cancer
October 19, 2023 13:09 - 22 minutes - 20.8 MBThe fourth episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features an introductory discussion on bladder cancer. Do you have questions or a suggestion for a future topic? Email our hosts: [email protected] References from the show: Bladder Cancer Canada Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, ...
2 Pees In A Pod Podcast - Ep 3 - Urinary tract infections in women
October 11, 2023 19:17 - 24 minutes - 22.1 MBThe third episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on urinary tract infections in women. Do you have questions or a suggestion for a future topic? Email our hosts: [email protected] Disclaimer: The information provided in this podcast is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advic...
2 Pees In A Pod Podcast - Ep 2 - Male voiding disorders and Benign Prostatic Hyperplasia (BPH)
October 04, 2023 18:41 - 32 minutes - 29.6 MBThe second episode of the 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz. This episode features a discussion on male voiding disorders and Benign Prostatic Hyperplasia (BPH). Do you have questions or a suggestion for a future topic? Email our hosts: [email protected] References from the show: CUA BPH Guidelines - Google Search Welcome to Canadian Urological Association | Canadian Urological Association (cua.org) Disclaimer: The information ...
2 Pees In A Pod Podcast - Ep 1 - PSA and Prostate Cancer Screening
September 27, 2023 18:47 - 28 minutes - 26.5 MBOur inaugural 2 Pees In A Pod Podcast series hosted by Dr Alan So and Dr Claudia Chavez-Munoz! This first podcast in the series focuses on PSA and Prostate Cancer Screening. Do you have questions or a suggestion for a future topic? Email our hosts: [email protected] References from the show: UPDATE – 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis - PMC (nih.gov) UBC & VGH Centre of Excellence | Vancouver Prostate Centre W...
CUA Highlights of ESMO 2022 - Kidney Cancer Session - French
October 01, 2022 16:25 - 43 minutes - 40.1 MBProgram Chair: Ricardo Rendon Kidney Cancer Panelists: Melissa Huynh, Lori Wood Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
CUA Highlights of ESMO 2022 - Kidney Cancer Session - English
October 01, 2022 16:20 - 43 minutes - 40.1 MBProgram Chair: Ricardo Rendon Kidney Cancer Panelists: Melissa Huynh, Lori Wood Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
CUA Highlights of ESMO 2022 - Bladder Cancer Session - French
October 01, 2022 16:15 - 41 minutes - 37.7 MBProgram Chair: Ricardo Rendon Bladder Cancer Panelists: Peter Black, Maria Jiang Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
CUA Highlights of ESMO 2022 - Bladder Cancer Session - English
October 01, 2022 16:10 - 41 minutes - 38.3 MBProgram Chair: Ricardo Rendon Bladder Cancer Panelists: Peter Black, Maria Jiang Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
CUA Highlights of ESMO 2022 - Prostate Cancer Session - French
October 01, 2022 16:05 - 44 minutes - 41 MBProgram Chair: Ricardo Rendon Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
CUA Highlights of ESMO 2022 - Prostate Cancer Session - English
October 01, 2022 16:00 - 44 minutes - 41 MBProgram Chair: Ricardo Rendon Prostate Cancer Panelists: Ricardo Rendon, Sebastien Hotte, Scott Morgan Sponsors: Gold: Bristol Myers Squibb, Merck Silver: Astellas, EMD Serono Pfizer, Eisai, IPSEN, Janssen, Seagen
Jean Gregoire | CV Risk | Q&A Series - French
April 21, 2022 04:00 - 4 minutes - 10.5 MBJean Gregoire, MD, FRCP(C), FCCS, FACC, FACP University of Montreal Institut de cardiologie de Montreal
Jean Gregoire | CV Risk | Q&A Series
April 21, 2022 04:00 - 5 minutes - 5.02 MBJean Gregoire, MD, FRCP(C), FCCS, FACC, FACP University of Montreal Institut de cardiologie de Montreal
CUA Q & A Series – CV Risk Darryl Leong
April 21, 2022 04:00 - 12 minutes - 11.3 MBDarryl Leong, MD McMaster University
CUA Q & A Series – CV Risk Jean Gregoire
April 21, 2022 04:00 - 5 minutes - 5.02 MBJean Gregoire, MD, FRCP(C), FCCS, FACC, FACP University of Montreal Institut de cardiologie de Montreal
Fred Saad | CV Risk | Q&A Series - French
April 21, 2022 04:00 - 4 minutes - 10.8 MBFred Saad, MD, FRCS CHUM, Institut de cancer de Montreal/CRCHUM
Darryl Leong | CV Risk | Q&A Series
April 21, 2022 04:00 - 12 minutes - 11.3 MBDarryl Leong, MD McMaster University
Fred Saad | CV Risk | Q&A Series
April 21, 2022 04:00 - 5 minutes - 4.89 MBFred Saad, MD, FRCS CHUM, Institut de cancer de Montreal/CRCHUM
CUA Q & A Series – CV Risk Fred Saad
April 21, 2022 04:00 - 5 minutes - 4.89 MBFred Saad, MD, FRCS CHUM, Institut de cancer de Montreal/CRCHUM
Luke Lavallee | Bone Health Management in Prostate Cancer | Q&A Series
April 20, 2022 20:18 - 7 minutes - 6.61 MBSponsored by Amgen. Luke Lavallee Urologic Oncologist and Associate Scientist The Ottawa Hospital Ottawa Hospital Research Institute Disclosures: Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas Grant/Honorarium: Sanofi
Sophie Mottard | Bone Health Management in Prostate Cancer | Q&A Series
April 20, 2022 20:14 - 20 minutes - 18.5 MBSponsored by Amgen. Sophie Mottard Orthopedic Oncology Surgeon Maisonneuve-Rosemont Hospital CHU Saint-Justine and Santa Cabrini Hospital Disclosures: Payment: Amgen (conference speaker)
David Kendler | Bone Health Management in Prostate Cancer | Q&A Series
April 20, 2022 04:15 - 15 minutes - 14 MBSponsored by Amgen. David Kendler Endocrinologist and Clinical Professor UBC Disclosures: Advisory Board: Amgen, Paladin, Biosynt Speakers Bureau: Amgen Payment: Amgen, Biosynt, Radius Pharma, Paladin Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin Clinical Trial: Radius Pharma Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executive)
Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones
April 20, 2022 04:00 - 1 hour - 155 MBDisclosures: Hassan Razvi Patent: Cook Urological Clinical Trials: Boston Scientific, Verity Pharma Leadership/board position: AUA, Endourology Society Olivier Traxer Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU
Why the Tm:Fibre Laser is Superior to the Ho:YAG for Urinary Stones - French
April 20, 2022 04:00 - 1 hour - 155 MBDisclosures: Hassan Razvi Patent: Cook Urological Clinical Trials: Boston Scientific, Verity Pharma Leadership/board position: AUA, Endourology Society Olivier Traxer Consultant: Karl Storz, Coloplast, IPG Medical, ROCAMED, Boston Scientific, Quanta, AMBU
CUA Q & A Series | Bone Health Management in Prostate Cancer - Luke Lavallee
April 04, 2022 20:18 - 7 minutes - 6.61 MBCUA Q & A Series | Bone Health Management in Prostate Cancer - Luke Lavallee Sponsored by Amgen. Speakers: Luke Lavallee Urologic Oncologist and Associate Scientist The Ottawa Hospital Ottawa Hospital Research Institute Disclosures: Luke Lavallee Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas Grant/Honorarium: Sanofi
CUA Q & A Series | Bone Health Management in Prostate Cancer - Sophie Mottard
April 04, 2022 20:14 - 20 minutes - 18.5 MBCUA Q & A Series | Bone Health Management in Prostate Cancer - Sophie Mottard Sponsored by Amgen. Speakers: Sophie Mottard Orthopedic Oncology Surgeon Maisonneuve-Rosemont Hospital CHU Saint-Justine and Santa Cabrini Hospital Disclosures: Sophie Mottard Payment: Amgen (conference speaker)
CUA Q & A Series | Bone Health Management in Prostate Cancer - David Kendler
April 04, 2022 04:00 - 15 minutes - 14 MBCUA Q & A Series | Bone Health Management in Prostate Cancer - David Kendler Sponsored by Amgen. Speakers: David Kendler Endocrinologist and Clinical Professor UBC Disclosures: David Kendler Advisory Board: Amgen, Paladin, Biosynt Speakers Bureau: Amgen Payment: Amgen, Biosynt, Radius Pharma, Paladin Grant/Honorarium: Amgen, Biosynt, Radius Pharma, Paladin Clinical Trial: Radius Pharma Leadership/Board Position: Specialists of BC, Drs. of BC section of Endocrinology (executiv...
CUA Highlights of GU ASCO 2022 - Bladder Cancer Session - French
February 22, 2022 05:00 - 42 minutes - 97.6 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Nimira Alimohamed Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen Wassim Kassouf No disclosures Alejandro Berlin No disclosures
CUA Highlights of GU ASCO 2022 - Bladder Cancer Session
February 22, 2022 05:00 - 42 minutes - 39 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Nimira Alimohamed Advisory Board/Consultancy roles: Pfizer, EMD Serono, Merck, Seagen Wassim Kassouf No disclosures Alejandro Berlin No disclosures
CUA Highlights of GU ASCO 2022 - Prostate Cancer Session
February 22, 2022 05:00 - 47 minutes - 43.1 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Tamim Niazi Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring Krista Noonan Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfi...
CUA Highlights of GU ASCO 2022 - Kidney Cancer Session - French
February 22, 2022 05:00 - 49 minutes - 113 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Christian Kollmannsberger Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Aste...
CUA Highlights of GU ASCO 2022 - Kidney Cancer Session
February 22, 2022 05:00 - 49 minutes - 45.3 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Christian Kollmannsberger Consultant: Pfizer, Merck, Sanofi, Astellas, BMS, Ipsen, Eisai, Bayer Honoraria for presentations: Pfizer, Ipsen, Eisai, BMS, Janssen, Bayer Scientific Advisory Board: Pfizer, Novartis, Ipsen, Eisai, Sanofi, Aste...
CUA Highlights of GU ASCO 2022 - Prostate Cancer Session - French
February 22, 2022 05:00 - 47 minutes - 108 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position Tamim Niazi Honoraria/ research funding: Abbvie, Astellas, Bayer, Janssen, Sanofi, Merck, AstraZeneca, TerSera, Knight Therapeutics, Amgen, Tolmar, Sanofi, Ferring Krista Noonan Consultancy-Astellas, AstraZeneca, EMD Serono, Janssen, Pfi...
CUA Practice Changing Publications (PCP) - Endourology (Surgical Management of BPH)
February 15, 2022 05:00 - 58 minutes - 53.3 MBDisclosures: Dean Elterman Advisory Boards/ Speakers Bureaus: Astellas, Boston Scientific, Duchesnay, Pfizer, Procept, Prodeon, Olympus, Medtronic, Urotronic, Zeneflow Kevin Zorn Advisory Board: BSCI, Procept, Zenflow
V2P2 2022 - An Update in Advanced Prostate Cancer - French
February 10, 2022 05:00 - 1 hour - 140 MBDisclosures: Fred Saad Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi Eleni Efstathiou Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant
V2P2 2022 - An Update in Advanced Prostate Cancer
February 10, 2022 05:00 - 1 hour - 56.1 MBDisclosures: Fred Saad Grants/Honoraria: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi Eleni Efstathiou Research Support/P.I.: Janssen, Sanofi-Genzyme, Astellas/Medivation, Oric-Pharma, Nuvation Scientific Advisory Board/Honoraria: Janssen, Sanofi-Genzyme, Bayer, Oric Pharma, Marck, AAA-Novartis, Genetech, Astra-Zeneca, Astellas, Pfizer, Myovant
Practice Changing Publications (PCP): Update in Kidney Cancer
February 01, 2022 05:00 - 1 hour - 57.3 MBDisclosures: Anil Kapoor Advisory Honoraria: BMS, MERCK, Ipsen, Eisai, Abbvie, Janssen, Astellas, Astra-Zeneca Speakers Bureau: Merck, Ipsen, Eisai Investments: Verity, Point Biopharma Clinical Trials: CCTG, Eisai, Janssen, Merck Leadership/Board Position: Kidney Cancer Canada Luke Lavallee Advisory Board: Sanofi, Ferring, Knight, Bayer, Janssen, Astellas Grant/Honorarium: Sanofi
The Year Ahead 2022: Global Economic Outlook
January 24, 2022 05:00 - 57 minutes - 52.4 MBDisclosures: Derek Henderson Banking relationship with TD Christopher French Advisory Boards: Astellas, AstraZeneca
Practice Changing Publications (PCP): Female Urology
December 07, 2021 05:00 - 51 minutes - 47.6 MBDisclosures: Martine Jolivet Advisory Board and/or Speaker Bureau: Allergan/Abbvie Genevieve Nadeau Clinical Trials: Contiform International Advisory Board and/or Speaker Bureau: Pfizer, Boston Scientific, Astellas, Allergan/Abbvie, Searchlight Pharma
Management of Medication-Refractory Overactive Bladder (OAB)
November 24, 2021 05:00 - 1 hour - 64.3 MBDisclosures: Kevin Carlson Advisory Board/Payment: Abbvie Richard Baverstock Advisory Board: Abbvie Speakers Bureau: Astellas, Boston Scientific, Abbvie Payment: Abbvie, Astellas, Bsci Greg Baily Advisory Board/ Speaker Bureau: Abbvie
Management of Medication-Refractory Overactive Bladder (OAB) - French
November 24, 2021 05:00 - 1 hour - 160 MBDisclosures: Kevin Carlson Advisroy Board/Payment: Abbvie Richard Baverstock Advisory Board: Abbvie Speakers Bureau: Astellas, Boston Scientific, Abbvie Payment: Abbvie, Astellas, Bsci Greg Baily Advisory Board/ Speaker Bureau: Abbvie
Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English)
November 18, 2021 05:00 - 1 hour - 63.1 MBDisclosures: Neil Fleshner Payment: Astellas, Janssen, Abbvie, Sanofi, Merck Grant/Honorarium: Astellas, Janssen, Bayer Investments: Verity Pharma Clinical Trials: Astellas, Janssen, Bayer Leadership Position: Point Biopharma Urban Emmenegger Advisory Boards: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca Payment: Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca Grant/Honorarium: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca Clinica...
Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French)
November 17, 2021 05:00 - 1 hour - 185 MBConflits d'interests: Fred Saad Subventions/honoraires: Amgen, Astellas, AstraZeneca, Bayer, Merck, Novartis, Janssen, Myovant, Sanofi Zineb Hamilou Remuneration: AstraZeneca, Sengen, EMD Serono Essai Clinique: Sengen Evan Weber Subventions ou des honoraires: AstraZeneca/Merck
V2P2 2022 - Female Sexual Dysfunction [FR]
November 15, 2021 05:00 - 59 minutes - 136 MBDisclosures: Ashley Cox Advisory Board: Abbvie, Allergan Rachel S. Rubin Speakers Bureau: Sprout Clinical Trials: Ipsen, Abbvie Leadership/Board Position: ISSWSH
V2P2 2022 - Female Sexual Dysfunction
November 15, 2021 05:00 - 59 minutes - 54.6 MBDisclosures: Ashley Cox Advisory Board: Abbvie, Allergan Rachel S. Rubin Speakers Bureau: Sprout Clinical Trials: Ipsen, Abbvie Leadership/Board Position: ISSWSH
CUA Practice Changing Publications (PCP): TESTIS CANCER
November 02, 2021 04:00 - 1 hour - 55.6 MBDisclosures: Armin Aprikian Advisory boards: Abbvie, Astellas, Bayer Grant/Honorarium: Abbvie, Astellas, Bayer, Sanofi, TerSera Robert Hamilton Advisory boards: Janssen, Astellas, Bayer, TerSera Clinical Trials: Janssen, Bayer, Astellas
CUA Practice Changing Publications (PCP): INFERTILITY
October 19, 2021 04:00 - 1 hour - 57.9 MBDisclosures: Armand Zini Shareholder in YAD Tech - a neutraceuticals company Jesse Ory No disclosures
CUA Highlights of ESMO 2021 - Prostate Cancer Session - French
September 22, 2021 04:00 - 48 minutes - 111 MBDisclosures: Sebastien J. Hotte Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem Grants (Institution): BMS, Janssen, Bayer Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen Tamim Nizai Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA Andrea Kokorovi...
CUA Highlights of ESMO 2021 - Prostate Cancer Session
September 22, 2021 04:00 - 48 minutes - 44.2 MBDisclosures: Sebastien J. Hotte Research Funding (Institution): Astellas, AstraZeneca, Ayala, Bayer, BMS, Eisai, Exelixis, Janssen, Ipsen, Merck, Roche, Sanofi, SeaGen, SignalChem Grants (Institution): BMS, Janssen, Bayer Consultant/Honoraria (Self): Astellas, AtraZeneca ,Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, Roche, SeaGen Tamim Nizai Honoraria/Research fun: Abbvie, Sanofi, TerSera, Knight Therapeutics, AstraZeneca, Bayer, Astellas, Janssen, Merck, Amgen, AAA Andrea Kokorovi...
CUA Highlights of ESMO 2021 - Kidney Cancer Session - French
September 22, 2021 04:00 - 44 minutes - 102 MBDisclosures: Michael Leveridge Ipsen - speaker session moderator 2019 Maryam Soleimani Honorarium: Pfizer Grant funding: Abbvie, Astellas, Bayer Himu Lukka No disclosures